多西他赛联合表柔比星/吡柔比星新辅助治疗对乳腺癌患者血清肿瘤标志物的影响

黄河清

[摘要]目的 探討多西他赛（DOC）联合表柔比星（EPI）或吡柔比星（THP）新辅助治疗对乳腺癌患者血清肿瘤标志物的影响。方法 回顾分析我院乳腺科2014年1月～2016年12月之间收治100例乳腺癌患者的临床资料，按照化疗方案的不同将其分为对照组和观察组，对照组接受卡培他滨联合EPI或THP方案治疗，观察组接受DOC联合EPI或THP方案治疗，比较分析两组患者临床疗效及对血清肿瘤标志物的影响。结果 对照组患者总有效率为58.0%，观察组患者总有效率为74.0%，两组比较差异有统计学意义（P<0.05）；两组患者治疗前CEA、CA125、CA153肿瘤标志物比较差异无统计学意义（P>0.05）；观察组、对照组治疗后CEA、CA125、CA153肿瘤标志物均明显低于组内治疗前，且差异均有统计学意义（P<0.05），观察组患者治疗后CEA、CA125、CA153肿瘤标志物均明显低于对照组治疗后，且差异均有统计学意义（P<0.05）。结论 乳腺癌患者接受多西他赛联合表柔比星或吡柔比星辅助化疗效果显著，有助于降低血清肿瘤标志物，值得临床推广。

[关键词]乳腺癌；辅助化疗；多西他赛；表柔比星；吡柔比星；卡培他滨

[中图分类号] R737.9 [文献标识码] A [文章编号] 2095-0616（2017）20-39-04

Effect of docetaxel combined with neoadjuvant therapy of epirubicin/pirarubicin on serum tumor markers in patients with breast cancer

HUANG Heqing

Department of Galactophore， the People's Hospital of Dongguan City， Dongguan 523059， China

[Abstract] Objective To investigate the effect of docetaxel（DOC） combined with neoadjuvant therapy（EPI） of epirubicin（EPI） or pirarubicin（THP） on serum tumor markers in patients with breast cancer. Methods The clinical data of 100 patients with breast cancer in galactophore department of our hospital were analyzed retrospectively， and were divided into control group and observation group according to the different chemotherapy treatment methods. The patients of control group were given the combination of capecitabine with EPI or THP programme therapy， the patients of observation group were given DOC combined with EPI or THP programme therapy， and the clinical efficacy and the impact of serum tumor markers of two groups were compared. Results The total effective rate of control group was 58.0%， while the total effective rate of the observation group was 74.0%， and the difference between the two groups was statistically significant（P<0.05）. Before treatment， there was no statistically significant difference between the tumor markers of CEA， CA125 and CA153 of two groups （P>0.05）. The tumor markers of CEA， CA125 and CA153 in the observation group and the control group were significantly lower than those before treatment respectively， and the differences were statistically significant（P<0.05）. And the tumor markers of CEA， CA125 and CA153 in the observation group were significantly lower than those in the control group（P<0.05）， and the differences were statistically significant（P<0.05）. Conclusion The efficacy of docetaxel combined with epirubicin or pirarubicin in the treatment of breast cancer is significant， which can helpful to reduce the serum tumor markers and deserve clinical promotion.endprint

[Key words] Breast cancer； Adjuvant chemotherapy； Docetaxel； Epirubicin； Pirarubicin； Capecitabine

乳腺癌是一种全球范围内较为常见的女性恶性肿瘤，全球每年新增乳腺癌患者在130万左右，且每年死亡病例数在40万以上，可见，乳腺癌的发生对女性生活质量和身体健康造成了严重的威胁[1]。随着临床医疗技术的发展完善以及临床研究的逐步深入，乳腺癌的临床治疗方法也日渐丰富，包括全身性化学药物治疗、放射治疗、外科手术等在内的综合性治疗方法已经逐渐成为了乳腺癌患者临床首选的治疗方法。氟尿嘧啶、环磷酰胺、吡柔比星等均为传统临床常用的辅助化疗药物，但整体治疗效果有限。多西他赛作为第三代微管微丝抑制类药物，则表现出了较为显著的优势。本研究对乳腺癌新辅助化疗中多西他赛联合表柔比星（EPI）或吡柔比星（THP）的应用价值进行了分析。……